Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORBIT EXPANSE long-term extension study of navenibart in hereditary angioedema
MOH_2026-01-19_015611Phase 3Not yet recruiting
- Sponsor
- Astria Therapeutics
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of navenibart in hereditary angioedema (HAE) (3 arms), sponsored by Astria Therapeutics. Primary endpoint: Long-term safety and tolerability. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2026-01-19_015611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-19_015611.